Navigation Links
Slovenia's Sole Radiotherapy Hospital Unveils Novalis Tx(TM) Platform From Varian and BrainLAB
Date:12/21/2009

ital also treats several hundred new cancer cases each year with brachytherapy. The lack of radiotherapy capacity in Slovenia, a country of just under two million inhabitants, has led to long waiting lists.

"Even though we work in two shifts using the six megavoltage treatment machines, our capacity is clearly insufficient to meet the current standard of fifty percent of cancer patients that should receive radiotherapy during the course of their disease," says Professor Primoz Strojan, head of the radiotherapy department. "All patients with cancer that need radiotherapy have to come to our hospital. With Novalis Tx and RapidArc technology we are gaining a powerful weapon in our fight against cancer which should have, among many other benefits, a positive influence on bringing down waiting lists."

The Novalis Tx radiosurgery platform features very high dose delivery rates, which contributes to shorter treatment times. It also offers dynamic fine beam shaping and non-invasive, precise patient positioning for rapid and more comfortable treatments. Specialized X-ray imaging systems are used to pinpoint the target and position the patient with millimeter accuracy, compensating for any motion that occurs during a treatment.

Bozidar Casar says the clinic will be ready to deliver the full range of treatments when the Novalis Tx radiosurgery platform with RapidArc capability is commissioned in mid-2010.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier sup
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Radiotherapy Pioneers Deliver First Varian RapidArc(TM) Treatment for Rectal Carcinoma Patient
2. Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments
3. Fighting Prostate Cancer With Speed and Accuracy: RapidArc(R) Radiotherapy Available at the Delaware Valley Urology Cancer Treatment Center
4. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
5. Eastern Europes First Novalis Tx(TM) Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc(R) Technology
6. New Research Shows Effectiveness of Stereotactic Body Radiotherapy for Spinal Tumors
7. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
8. Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology
9. Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer
10. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
11. Pitcher Joaquin Benoit, PADF Team Up to Send a Much-Needed Christmas Present to Haitis Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... EDISON, N.J. , Aug. 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... Sapirstein , Chief Executive Officer, will present live ... DATE: Thursday, August 6, 2015 TIME: 12:15PM EDT ... will be a live, interactive online event where ...
(Date:8/4/2015)... Aug. 4, 2015 Among 1,000 U.S. consumers, ... only half of consumers surveyed are aware of prescription ... used use them, according to findings from a new ... service partnership focused on improving the health and well-being ... survey polled 1,000 men and women, ages 21 and ...
(Date:8/4/2015)... Calif., Aug. 4, 2015  Syneron Medical Ltd. (NASDAQ: ... financial results for the three month period ended June 30, ... Non-GAAP 1 Highlights: , Revenue ... currency. , North American product sales grew 45% year-over-year. ... constant currency, including 14% product growth in the EMEA region ...
Breaking Medicine Technology:ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 2Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 3Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 4Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 5Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 6Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 7Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 8Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 9Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 10Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 11Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 12Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 13Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 14Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 15Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 16Syneron Medical Reports Revenue of $73.5 Million for the Second Quarter 2015 17
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 2PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 3PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 4PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 5PARI Pharma's Altera Delivers Gilead's Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 2Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 3Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 4Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 5Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 6Diabetics Twice as Likely to Have Hearing Loss; North Carolina HearUSA Centers to Offer Free Hearing Screening and Diabetes Video in March 7
(Date:8/4/2015)... ... 04, 2015 , ... Sin City Gallery is delighted to ... diverse group of exceptionally talented female artists. The exhibition premieres at the ... 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura Henkel, ...
(Date:8/4/2015)... ... August 04, 2015 , ... MedicaSoft ... Office of the National Coordinator for Health Information Technology (ONC-HIT) 2014 Edition ... highest quality personal health record and patient portal solution to healthcare providers ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may decline ... driving, says the August 2015 Harvard Health Letter. , "Age and health conditions ... an individual assessment of skills," says Lissa Kapust, a social worker at Harvard-affiliated ...
(Date:8/4/2015)... ... ... METTLER TOLEDO has announced an upcoming online symposium entitled ... and Merck. This free online seminar will be held on September 24, ... decisions with limited process understanding. Established methods have been developed to facilitate ...
(Date:8/4/2015)... ... August 04, 2015 , ... Half of consumers ... is board-certified is increasingly influential in their choice of practitioner, according to new ... Consumer Survey on Cosmetic Dermatologic Procedures reflects overall consumer views on cosmetic medical ...
Breaking Medicine News(10 mins):Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 2Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 3Health News:ASDS Survey: Half of Consumers Considering Cosmetic Procedure 4
... without gestational diabetes signals future heart risk, researcher says. , ... given to pregnant women may also show if they have ... new study has found. , This finding is important because ... for gestational diabetes to identify women who are at risk ...
... Aug. 24 /PRNewswire-Asia-FirstCall/ -- China Kangtai Cactus,Biotech, Inc. (OTC ... marketer of a variety of cactus-based products in,China, announced ... attend investor conference and meet with U.S. investors in ... roadshow details: , The company ...
... , WASHINGTON, Aug. 24 Secretary of ... (VA) is taking steps to assist Veterans seeking compensation for Post-Traumatic ... of war are being addressed vigorously and comprehensively by this administration ... century," said Secretary Shinseki. , , The VA ...
... , , AUBURN HILLS, ... (OTC Bulletin Board: ECOC), a leader in the discovery ... that it has signed a collaboration agreement with a ... for producing "fire standard compliant" (FSC) cigarettes. FSC cigarettes ...
... , ABBOTT PARK, Ill., Aug. 24 ... has received approval from Health Canada for the XIENCE V(R) Everolimus ... (CAD). XIENCE V is the only drug eluting stent to have ... the primary endpoints of two randomized, pivotal (phase III) clinical trials. ...
... , , CINCINNATI and ARDEE, Ireland, Aug. 24, ... Warner Chilcott plc (Nasdaq: WCRX ) today announced an agreement for ... cash payment of $3.1 billion. , , To view ... m nr/pg/39814/ , , (Logo: ...
Cached Medicine News:Health News:Glucose Challenge in Pregnancy Could Predict Heart Disease 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 2Health News:China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September 3Health News:Secretary Shinseki Moves to Simplify PTSD Compensation Rules 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 2Health News:Ecology Coatings Signs Development Agreement with Major U.S. Tobacco Company 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 2Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 3Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 4Health News:Health Canada Approves Abbott's XIENCE V(R) Drug Eluting Stent 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 2Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 3Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 4Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 5Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 6Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 7Health News:Warner Chilcott Acquires P&G's Global Pharmaceuticals Business 8
...
... Tupos LV/A+, the single-lead principle has been applied ... The complete system, which consists of the Tupos ... the scope of surgery and the risk of ... and the ventricle via a single lead. The ...
... ICD cardiac resynchronization and ICD device offers ... The unit's RV only sensing provides no ... LV depolarizations, eliminating this cause of inappropriate ... LV separation for optimized hemodynamics. Proven PR ...
... The Medtronic InSync II Marquis incorporates ... ICD therapy. Cardiac resynchronization benefits include ... pacing outputs to unique patient needs. ... functions that help physicians manage heart ...
Medicine Products: